Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (511-520 of 652) with videos related to

Pageof 66
Sort By:
Blood|September 25, 2025
Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenström macroglobulinemiaTina Bagratuni, Ourania Theologi, Christos Vlachos, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer GroupAristotelis Bamias, Konstantinos Koutsoukos, Nikos Gavalas, et al.
Clinical Immunology (Orlando, Fla.)|December 31, 2022
Early prediction of COVID-19 outcome using artificial intelligence techniques and only five laboratory indicesPanagiotis G Asteris, Styliani Kokoris, Eleni Gavriilaki, et al.
Cancer Medicine|March 3, 2023
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 studyAlexander Lesokhin, Richard LeBlanc, Meletios A Dimopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2021
Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 StudyMarie José Kersten, Karima Amaador, Monique C Minnema, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2021
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE StudyChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Leukemia Research|May 8, 2010
Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)Efstathios Kastritis, Marie-Christine Kyrtsonis, Evdoxia Hadjiharissi, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 28, 2020
Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosisEfstathios Kastritis, Despina Fotiou, Foteini Theodorakakou, et al.
American Journal of Hematology|October 9, 2014
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myelomaRobert Z Orlowski, Liana Gercheva, Cathy Williams, et al.
Circulation Research|August 13, 2019
Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain AmyloidosisKimon Stamatelopoulos, Georgios Georgiopoulos, Fani Athanasouli, et al.
Pageof 66

Showing results (511-520 of 652) with videos related to

Sort By:
Pageof 66
Blood|September 25, 2025
Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenström macroglobulinemiaTina Bagratuni, Ourania Theologi, Christos Vlachos, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer GroupAristotelis Bamias, Konstantinos Koutsoukos, Nikos Gavalas, et al.
Clinical Immunology (Orlando, Fla.)|December 31, 2022
Early prediction of COVID-19 outcome using artificial intelligence techniques and only five laboratory indicesPanagiotis G Asteris, Styliani Kokoris, Eleni Gavriilaki, et al.
Cancer Medicine|March 3, 2023
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 studyAlexander Lesokhin, Richard LeBlanc, Meletios A Dimopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2021
Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 StudyMarie José Kersten, Karima Amaador, Monique C Minnema, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2021
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE StudyChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Leukemia Research|May 8, 2010
Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)Efstathios Kastritis, Marie-Christine Kyrtsonis, Evdoxia Hadjiharissi, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 28, 2020
Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosisEfstathios Kastritis, Despina Fotiou, Foteini Theodorakakou, et al.
American Journal of Hematology|October 9, 2014
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myelomaRobert Z Orlowski, Liana Gercheva, Cathy Williams, et al.
Circulation Research|August 13, 2019
Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain AmyloidosisKimon Stamatelopoulos, Georgios Georgiopoulos, Fani Athanasouli, et al.
Pageof 66